UK's Bioventix half-year revenue, profit decline amid China market challenges

Bioventix

30/03/2026 07:11

Overview

UK monoclonal antibody supplier's half-year revenue declined yr/yr, with pretax profit also falling

Tau/neuro royalties for Alzheimer's assays increased five-fold during the reporting period

Sales of core antibodies were broadly in line with last year; limited revenue loss in China

Outlook

Company says trading remains in line with expectations for year ending 30 June 2026

Result Drivers

TAU/NEURO ROYALTIES - Co said royalties from Tau/neuro antibodies for Alzheimer's assays increased five-fold during the period

CORE ANTIBODIES - Sales of vitamin D and other core antibodies were broadly in line with last year, reflecting mature diagnostic products

CHINA REVENUE LOSS - Co said challenging market conditions in China led to loss of some limited revenue streams

Company press release: ID:nRSd5106Ya

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
GBP 6.16 mln
H1 Pretax Profit
GBP 4.85 mln


Analyst Coverage

Wall Street's median 12-month price target for Bioventix PLC is GBp3,900.00, about 183.6% above its March 27 closing price of GBp1,375.00

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)